Day: June 8, 2022

BERKELEY HEIGHTS, N.J., June 08, 2022 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that management will be participating in a fireside chat at the JMP Securities Life Sciences Conference being held in New York on June 15 – 16, 2022.JMP Securities Life Sciences Conference:   Date: Wednesday, June 15, 2022Time: 10:30am EDTWebcast Link  About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company is focused on developing its lead product DefenCath™, a novel, antibacterial and antifungal...

Intuitive, enterprise-grade tools enable businesses to create dynamic, interactive video with Vimeo NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) — Vimeo (NASDAQ:VMEO), the world’s leading all-in-one video software solution, today announced the launch of new interactive video capabilities with Vimeo. This launch marks the successful integration of the WIREWAX feature-set after its acquisition by Vimeo last November. “We believe that most business videos will include some form of interactivity in the future, because it’s a proven, more effective way to engage audiences of all kinds,” said Mark Kornfilt, President and Chief Product Officer, Vimeo. “One of Vimeo’s greatest abilities is to take the complex and make it simple. We’ve brought the sophisticated capabilities of WIREWAX to our industry-leading platform so that anyone can...

Manhattan has the industry’s most robust WMS and deepest and broadest set of supply chain execution solutions ATLANTA, June 08, 2022 (GLOBE NEWSWIRE) — Manhattan Associates Inc. (NASDAQ: MANH), a global leader in supply chain commerce solutions, today announced that it has been named a Leader in Gartner Magic Quadrant for Warehouse Management Systems1 for the 14th time in a row. The report evaluated 17 vendors this year and Manhattan once again placed highest in its ability to execute and furthest right on completeness of vision. Manhattan has been named a Leader in every Gartner WMS Magic Quadrant since the report’s inception in 2006. The company is also a trailblazer in unifying warehouse, labor management, automation, transportation and yard management into a comprehensive supply chain execution solution. Backed by the industry’s...

Multi-channel streaming platform and consent enablement leaders partner to provide embedded first-person consent controls to empower consumers to control their data GLENDALE, CA, June 08, 2022 (GLOBE NEWSWIRE) — via NewMediaWire –  Loop Media, Inc. (“Loop Media” or “Loop”) (OTC: LPTV), a leading multi-channel streaming platform that provides curated music video and branded entertainment channels for businesses today announced a partnership with Qonsent, the first consent enablement and consumer trust platform. The partnership will embed Qonsent’s first-person consent technology into Loop Media’s streaming platform to ensure that Loop’s business clients accessing content are able to quickly and easily understand, agree to and give their consent to having their data seen by Loop. Loop clients will also have the ability to interact...

ELMSFORD, N.Y., June 08, 2022 (GLOBE NEWSWIRE) — Party City Holdco Inc. (NYSE: PRTY) today announced that the Company is scheduled to participate in a fireside chat at the Oppenheimer 22nd Annual Consumer Growth and E-Commerce Conference, on Wednesday, June 15, 2022 at 2:15 p.m. Eastern Time. A link to the live webcast will be available via the Company’s web site, investor.partycity.com. Participants should log in approximately 10 minutes prior to the start of the event. An online replay will also be available following the event. About Party City Party City Holdco Inc. (PCHI) [NYSE:PRTY] is a global leader in the celebrations industry. A vertically integrated designer, manufacturer, distributor and retailer, PCHI offers consumer party goods in more than 100 countries around the world. PCHI operates multiple business divisions,...

Oral presentation to include additional durability data from patients treated with NTLA-2001, the first-ever systemically administered in vivo CRISPR investigational therapy Presentation to include data supporting fixed dose selection in the ongoing single-dose expansion cohort of polyneuropathy armCAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that interim clinical data from the Phase 1 study of NTLA-2001, an investigational therapy in development for the treatment of transthyretin (ATTR) amyloidosis, will be shared in an oral presentation at the European Association for the Study of the Liver’s International Liver Congress™ 2022, taking place...

BBS-Bioactive Bone Substitutes Plc, Company Announcement, Insider information, 8 June 2022 2.30 p.m. (CEST) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN PART, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL. BBS-Bioactive Bone Substitutes Plc’s rights issue raised gross proceeds of EUR 3.5 million The rights issue resolved by BBS-Bioactive Bone Substitutes Plc’s (“BBS” or the “Company”) Board of Directors on 6 May 2022 (the “Offering”) has been subscribed to 77 percent. The Company raised proceeds of approximately EUR 3.5 million from the Offering before deduction of issuance costs and fees. The Board of Directors of the Company resolved on 8 June 2022 to approve the subscriptions received in...

• PBML04 represents the company’s fourth program to receive IND clearance PHILADELPHIA, June 08, 2022 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PBML04, an adeno-associated virus (AAV)-delivery gene therapy that is being studied for the treatment of Metachromatic Leukodystrophy (MLD). MLD is a rare, fatal, pediatric, lysosomal storage disease that currently has limited available treatment options. “We are thrilled to have received IND clearance for our program in metachromatic leukodystrophy, marking our fourth IND clearance as a company and our third pediatric lysosomal...